360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

TESARO Inc

Type: Company

Name: TESARO Inc

Nationality: United States

Web Address: http://tesarobio.com/

First reported 17 hours ago - Updated 17 hours ago - 5 reports

Deutsche Bank AG

TESARO to Present at the Deutsche Bank 38th Annual 2013 Health Care Conference

(GLOBE NEWSWIRE) -- TESARO, Inc. announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President, will present at the Deutsche Bank 38th Annual 2013 Health Care Conference at the Westin Boston Waterfront Hotel on ... [Published Interest!ALERT - 17 hours ago]

Entities: TESARO Inc, Deutsche Bank AG, Health Care

First reported 18 hours ago - Updated 18 hours ago - 1 reports

BioMarin Pharmaceutical Inc

BioMarin Gains on Prospects for Experimental Cancer Drug

BioMarin Pharmaceutical Inc. (BMRN), a maker of drugs for rare diseases, rose the most in more than six months ahead of a medical conference where the company plans to publish data on its experimental cancer therapy.BioMarin gained 2.5 percent to $66.59 ... [Published Bloomberg - 18 hours ago]

Entities: BioMarin Pharmaceutical Inc, TESARO Inc, Cancer

First reported May 21 2013 - Updated May 21 2013 - 2 reports

TESARO Inc

Ambarella Inc (AMBA), Chuy’s Holdings Inc (CHUY): Are These Top Post-IPO Performers Still a Buy?

Investors are no stranger to large IPO pops, but in the last year we have seen incredible post-IPO runs, indicating that these companies were priced too cheap. Thus I am looking at the top five to determine if more upside exists.#5 Ambarella Inc (NASDAQ: ... [Published InsiderMonkey.com - May 21 2013]

Entities: Ambarella Inc, IPOs, TESARO Inc

First reported May 21 2013 - Updated May 21 2013 - 1 reports

American Society of Clinical Oncology

American Society Of Clinical Oncology Abstracts Point To Potential Profits

By :The American Society of Clinical Oncology (ASCO) posted its list of abstracts to be presented at the influential Annual Meeting May 30- June 4 last week and investors have been busy going through the information. Why? It is an accepted fact that biopharmaceutical ... [Published Seeking Alpha - May 21 2013]

Entities: American Society of Clinical Oncology, Medical Devices, TESARO Inc

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Aegerion Pharmaceuticals, Inc. (AEGR), TESARO Inc (TSRO), And Three Humongous Healthcare Stocks This Week

Up, up, and away. That’s the motto for the market as a whole so far this year, but it’s also especially applicable for a select group of stocks. Here are three humongous health-care stocks for the past week.$1 billion has a nice ring to itWhen Aegerion ... [Published InsiderMonkey.com - May 20 2013]

Entities: TESARO Inc, Aegerion Pharmaceuticals Inc, Stocks, Halozyme Therapeutics Incorporated

First reported May 19 2013 - Updated May 19 2013 - 1 reports

Aegerion Pharmaceuticals Inc

The Best- And Worst- Performing Biotech Stocks, May 10 To May 17

These are the best and worst-performing medical and biotech stocks from May 10 to May 17, 2013. This screen includes biotechnology and medical companies traded on the New York Stock Exchange, the Nasdaq or the American Stock Exchange that had market capitalizations ... [Published Forbes.com - May 19 2013]

Entities: Biotechnology, Stocks, Aegerion Pharmaceuticals Inc

First reported May 19 2013 - Updated May 19 2013 - 1 reports

United States Patent And Trademark Office

Opko Updates on 1st Quarter 2013 Operating and Financial Hig. . .

Opko Updates on 1st Quarter 2013 Operating and Financial Highlights [Professional Services Close - Up]ProQuest Information & LearningOpko Health, Inc., a multi-national biopharmaceutical and diagnostics company, reported operating and financial highlights ... [Published Equities.com - May 19 2013]

Entities: Human Growth Hormone, Phase III, United States Patent And Trademark Office, TESARO Inc

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Vascular Files Patent Infringement Complaint Against Boston Scientific; Tesaro Demonstrate Activity in Ovarian and Breast Cancer

Vascular Solutions (Nasdaq: VASC) announced it has filed a patent infringement complaint in the U.S. District Court for the District of Minnesota against Boston Scientific Corporation (NYSE: BSX). The complaint alleges that Boston Scientific has infringed ... [Published BioMedReports - May 17 2013]

Entities: TESARO Inc, Boston Scientific Corp, Vascular Solutions Inc

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Market Wrap for Thursday, May 16: A Small Pullback For U.S. Stocks as Economic Data Disappoints

Stocks pulled back late on Thursday as bullish sentiment could not overcome disappointing economic reports. Initial jobless claims, housing starts and a reading of the Philadelphia Fed's Business Outlook Index all surprised to the downside. Although it ... [Published WorldNetDaily - May 16 2013]

Entities: TESARO Inc, NewStar Financial Inc, Aegerion Pharmaceuticals Inc, Infinity Pharmaceuticals Inc

First reported May 16 2013 - Updated May 16 2013 - 2 reports

4 Healthcare Stock Stories For Thursday Investing Wellness

Johnson & Johnson ( NYSE:JNJ ): Closing price $87.45J&J’s Janssen Biotech announced Thursday that the FDA has cleared Simponi (golimumab) for the treatment of moderately to severely active ulcerative colitis in adult patients who have shown corticosteroid ... [Published Wall St. Cheat Sheet - May 16 2013]

Entities: SciClone Pharmaceuticals Inc, SIMPONI, Johnson & Johnson

First reported May 16 2013 - Updated May 16 2013 - 4 reports

Tesaro, Inc. Announces Presentation of Niraparib Clinical Data at the 2013 American Society of Clinical Oncology Annual Meeting

(GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that final results from a Phase 1 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP), will be presented at the American Society ... [Published BioSpace - May 16 2013]

Entities: TESARO Inc, American Society of Clinical Oncology, Clinical Data Inc

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Human-to-human coronavirus spread looks likely

The coronavirus that has killed 18 people appears capable of human-to-human transmission, the WHO reports. A French patient who shared a room with an infected person now has the virus, too. No vaccine is available, but patients are reportedly responding ... [Published FierceVaccines - May 16 2013]

Entities: TESARO Inc, Coronavirus, Vaccine, MPI Research, Medical Devices

Quotes

...across most business fronts accelerated during the first quarter of 2013," said Phillip Frost, OPKO's Chairman and Chief Executive Officer. "We are pleased with the advances of our operating businesses, as well as the progress made in the development of our CTAP101 Capsules and 4Kscore prostate diagnostic test. Our solid financial position, coupled with anticipated revenue growth, will facilitate progress of our product pipeline, soon to include PROLOR's once a week human growth-hormone."

Opko Updates on 1st Quarter 2013 Operating and Financial Hig. . . [Published Equities.com - May 19 2013]

...blatant plagiarisms of a patented medical device that I have ever encountered," said Howard Root, Chief Executive Officer of Vascular Solutions. "Virtually every substantive aspect of our GuideLiner product and patents, from the design to the dimensions to even the exact words used in the product's deployment instructions, has been misappropriated by Boston Scientific and applied to their Guidezilla catheter. We do not take the initiation of patent litigation lightly, but this is exactly the type of conduct that patents were intended to protect – a small medical device company creating a completely new and innovative product only to be flagrantly violated by a knock-off brazenly marketed by the world's largest interventional cardiology company. We intend to move quickly to stop this violation of our rights."

Vascular Files Patent Infringement Complaint Against Boston Scientific; Tesaro Demonstrate Activi ... [Published BioMedReports - May 17 2013]

...Pappas. "I look forward to working with the organization and the board in developing policies that can further foster innovation and facilitate the creation of good jobs throughout the U S economy."

Art Pappas Elected to NVCA Board of Directors PR Newswire [Published Yahoo! Finance - May 15 2013]

...in patients with breast cancer during the second half of 2013 to complement our ovarian pivotal program," said Lonnie Moulder, CEO of TESARO. "We look forward to the presentation of the final Phase I II results for niraparib at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting and data supporting a reduced potential of drug interactions for rolapitant at the Multinational Association of Supportive Care in Cancer (MASCC) symposium."

TESARO Q1 net loss increases [Published Individual.com - May 07 2013]

More Content

sort by: Date \| Relevance
TESARO to Present at the Deutsche Bank 38th Ann... [Published Interest!ALERT - 17 hours ago]
TESARO to Present at the Deutsche Bank 38th Ann... [Published Morningstar.com - 17 hours ago]
TESARO to Present at the Deutsche Bank 38th Ann... [Published Reuters - 17 hours ago]
TESARO to Present at the Deutsche Bank 38th Ann... [Published OSIX News - 17 hours ago]
TESARO to Present at the Deutsche Bank 38th Ann... [Published GlobeNewswire - 17 hours ago]
BioMarin Gains on Prospects for Experimental Ca... [Published Bloomberg - 18 hours ago]
Ambarella Inc (AMBA), Chuy’s Holdings Inc (CHUY... [Published InsiderMonkey.com - May 21 2013]
Are These Top Post-IPO Performers Still a Buy? [Published Motley Fool - May 21 2013]
American Society Of Clinical Oncology Abstracts... [Published Seeking Alpha - May 21 2013]
Aegerion Pharmaceuticals, Inc. (AEGR), TESARO I... [Published InsiderMonkey.com - May 20 2013]
The Best- And Worst- Performing Biotech Stocks,... [Published Forbes.com - May 19 2013]
Opko Updates on 1st Quarter 2013 Operating and ... [Published Equities.com - May 19 2013]
Vascular Files Patent Infringement Complaint Ag... [Published BioMedReports - May 17 2013]
Market Wrap for Thursday, May 16: A Small Pullb... [Published WorldNetDaily - May 16 2013]
4 Healthcare Stock Stories For Thursday Investi... [Published Wall St. Cheat Sheet - May 16 2013]
Negative Day with Poor Close [Published Zecco - May 16 2013]
4 Healthcare Stock Stories For Thursday Investi... [Published Wall St. Cheat Sheet - May 16 2013]
Market Wrap for Thursday, May 16: A Small Pullb... [Published Benzinga.com - May 16 2013]
Tesaro, Inc. Announces Presentation of Nirapari... [Published BioSpace - May 16 2013]
Human-to-human coronavirus spread looks likely [Published FierceVaccines - May 16 2013]
TESARO Announces Presentation of Niraparib Clin... [Published Reuters - May 16 2013]
TESARO Announces Presentation of Niraparib Clin... [Published Yahoo! Finance - May 16 2013]
TESARO Announces Presentation of Niraparib Clin... [Published Morningstar.com - May 16 2013]
Art Pappas Elected to NVCA Board of Directors P... [Published Yahoo! Finance - May 15 2013]
Opko Reports First Quarter 2013 Operating and F... [Published Individual.com - May 14 2013]
Very Narrowly Mixed on the Day [Published Zecco - May 14 2013]
TESARO PT Raised to $45.00 at Deutsche Bank (TSRO) [Published American Banking News - Stock Ratings - May 13 2013]
OPKO HEALTH INC.: OPKO Announces First Quarter ... [Published 4 Traders - May 09 2013]
Tesaro, Inc. Announces Election of to Board of ... [Published BioSpace - May 09 2013]
OPKO Announces First Quarter 2013 Operating and... [Published Yahoo! Finance - May 09 2013]

Blogs

sort by: Date \| Relevance
4 Healthcare Stock Stories For Thursday Investi... [Published Wall St. Cheat Sheet - May 16 2013] Johnson & Johnson ( NYSE:JNJ ): Closing price $87.45J&J’s Janssen Biotech announced Thursday that the FDA has cleared Simponi (golimumab) for the treatment of moderately to severely active ulcerative colitis in adult patients who have shown corticosteroid ...
4 Healthcare Stock Stories For Thursday Investi... [Published Wall St. Cheat Sheet - May 16 2013] Johnson & Johnson ( NYSE:JNJ ): Closing price $87.45 J&J’s Janssen Biotech announced Thursday that the FDA has cleared Simponi (golimumab) for the treatment of moderately to severely active ulcerative colitis in adult patients who have shown corticosteroid ...
Frontrunning: April 26 [Published Zero Hedge - Apr 26 2013] Reinhart and Rogoff: Responding to Our Critics ( NYT ) Differences with centre-right delay Italy's Letta ( Reuters ) Italy's Letta moves forward to shape government ( Reuters ) China’s leaders warn on financial risks ( FT ) Norway oil fund makes big move ...
Financings of the Fortnight Wonders About The Wolf [Published The IN VIVO Blog - Mar 07 2013] Huffing and puffing and blowing the NIH down?The biggest financial news of the fortnight had to be the U.S. government’s failure to avoid the sequester budget cuts, and the odd collective yawn it produced. Even with the sword of Damocles poised ...
At J.P. Morgan Conference, Life-Science Investo... [Published WSJ.com: Venture Capital Dispatch - Jan 10 2013] Simon Dawson/Bloomberg News In its 31 years of bringing together health-care industry executives, investors and entrepreneurs, the J.P. Morgan Healthcare Conference has become a top venue for deal making. It’s also a place where you’ll hear plenty ...

Press Releases

sort by: Date \| Relevance
OPKO Announces First Quarter 2013 Operating and... [Published Business Wire - May 09 2013]
TESARO Announces Election of Dr. James Armitage... [Published GlobeNewswire: Advertising News - May 09 2013]
Tesaro Announces First-Quarter 2013 Operating R... [Published GlobeNewswire: Acquisitions News - Apr 25 2013]
TESARO to Announce First Quarter 2013 Financial... [Published GlobeNewswire: Acquisitions News - Apr 17 2013]
TESARO to Present at the 20th Annual Future Lea... [Published GlobeNewswire: Advertising News - Mar 28 2013]